Biomanufacturing technology roadmap

BioPhorum has produced a document on the technology and regulatory gaps in the continuous downstream processing of therapeutic proteins.

The Continuous Downstream Processing For Biomanufacturing: An Industry Review paper uses a mAb process as a model system and highlights the gaps that are preventing the use of continuous biomanufacturing.

It contains a gap analysis of a typical continuous mAb downstream process from
primary capture to bulk drug substance and aims to focus industry and supplier efforts on generating solutions.

The identified gaps are grouped into these categories:

  • unit operation technologies
  • single-use technologies
  • automation
  • modeling
  • regulatory.

Common terminology has also been defined to clarify their meaning. It is hoped that closing the gaps identified in this paper will turn the promise of continuous bioprocessing into a reality so that patients, biomanufacturers and suppliers may all
benefit.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Share This

Share this

Share this post with your colleagues.